Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy
Research · 2025-01 · 8
DOI: 10.34133/research.0712 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Research, online erschienen am 22.05.2025. Verfasst von Rui Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Zhejiang Provincial Outstanding Youth Science Foundation.
Abstract (Originalsprache)
Autoimmune kidney diseases (AIKDs) depict a range of disorders involving immune-mediated damage to the kidneys, where conventional biologic therapies involving monoclonal antibodies often prove insufficient because of persistent autoreactive B cell reservoirs in lymphoid organs and inflammatory tissues. The appearance of chimeric antigen receptor (CAR)-T cell therapies targeting B cells has shown transformative potential, with recent clinical trials showing the remarkable efficacy of anti-CD19 CAR-T cells in achieving profound B cell depletion, reducing immune complex deposition, and ameliorating renal inflammation in AIKDs. While these results highlight the potential of CAR-T cell therapy in facilitating immune reset and overcoming treatment resistance, further clinical investigations are imperative to establish its long-term safety and sustained therapeutic benefits. This review synthesizes current evidence on CAR-T cell applications in AIKDs, discusses critical considerations for clinical translation, identifies existing limitations and challenges, and proposes strategic directions for therapeutic optimization and advancement.
Autor:innen und Institutionen
- Department of Nephrology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China.
- Department of Laboratory Medicine, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China.
ORCID-Profile: Qing Ye
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Zhejiang Provincial Outstanding Youth Science Foundation
Zitieren
APA
Gu, R., Shen, J., Zhang, J., Mao, J., & Ye, Q. (2025). Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy. Research, 8. https://doi.org/10.34133/research.0712
Vancouver
Gu R, Shen J, Zhang J, Mao J, Ye Q. Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy. Research. 2025;8. doi:10.34133/research.0712
BibTeX
@article{Gu2025,
author = {Gu, Rui and Shen, Jiayi and Zhang, Jiayu and Mao, Jianhua and Ye, Qing},
title = {Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy},
journal = {Research},
year = {2025},
volume = {8},
doi = {10.34133/research.0712}
}
EUVIMED